KH001 Besylate for Premature Ejaculation | KH001 on Clinical Trial Drug Explained
Dr. Abdul Malik
scheduleUpcoming — Friday 4:00 PM EST
Premature ejaculation (PE) affects millions of men worldwide, and researchers are now investigating KH001 Besylate, an innovative investigational drug currently undergoing Phase 2 clinical trials as a potential on-demand treatment for lifelong premature ejaculation. KH001 Besylate for Premature Ejaculation | KH001 on Clinical Trial Drug Explained In this video, we explore: ✅ What is KH001 Besylate? ✅ Why it is considered a novel treatment approach ✅ How KH001 may work through serotonin transporter (SERT) inhibition and additional pharmacologic effects linked with ejaculation control pathways. ✅ Fast onset and short duration characteristics being investigated for on-demand use. ✅ Current clinical trial status and ongoing research.
